Breccia Massimo, Palandri Francesca, Polverelli Nicola, Caira Morena, Berluti Michela, Palumbo Giuseppe A, De Stefano Valerio
Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Università, Roma, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seragnoli, Bologna, Italy.
Front Oncol. 2024 Jul 24;14:1382872. doi: 10.3389/fonc.2024.1382872. eCollection 2024.
Myelofibrosis (MF) is a clonal disorder of hematopoietic stem cells characterized by altered bone marrow function and fibrosis. The aim of this narrative review is to report on the most recent epidemiologic data and to discuss features of MF and current strategies for the management of this condition in clinical practice. MF features covered by our review will include: characteristics of patients with MF; myeloproliferative and myelodepletive phenotypes; MF-associated thrombosis and bleeding; risk of infections; prefibrotic and overt PMF; secondary MF. Finally, we will discuss a few aspects of MF management in clinical practice and suggest strategies for its optimization and standardization. The focus of our paper is on Italy, but relevant data from other countries will also be reviewed.
骨髓纤维化(MF)是一种造血干细胞的克隆性疾病,其特征为骨髓功能改变和纤维化。本叙述性综述的目的是报告最新的流行病学数据,并讨论MF的特征以及临床实践中该疾病的当前管理策略。我们综述涵盖的MF特征将包括:MF患者的特征;骨髓增殖性和骨髓抑制性表型;MF相关的血栓形成和出血;感染风险;纤维化前期和明显的原发性骨髓纤维化;继发性MF。最后,我们将讨论临床实践中MF管理的几个方面,并提出优化和标准化策略。我们论文的重点是意大利,但也将回顾其他国家的相关数据。